Therapeutic use of peptide inhibitors of NADPH oxidase; aerosolization as a delivery mechanism
- Detailed Technology Description
- None
- *Abstract
-
BackgroundThe contribution of vascular isoforms of the NADPH oxidase (Nox1, Nox2 and Nox4) to the pathogenesis of cardiovascular and cardiopulmonary disease, such as pulmonary hypertension, is becoming increasingly clear. The development of therapeutics that selectively inhibit these isoforms is an intense area of investigation.TechnologyInvestigators have developed a specific peptide inhibitor of the endogenous oxidase, Nox2. Delivery of this peptide using an aerosolizer/nebulizer produced therapeutic concentation in mouse lungs. This inhibitor markedly attenuated cardiac hypertrophy in response to a severe from of experimental pulmonary hypertension.Application* Treatment for pulmonary hypertension and other cardiopulmonary diseasesAdvantages* Effective mechanism for delivery which can be easily adapted for clinical useStage of Development* in vivo dataNon provisional patent application filed
- *Principal Investigator
-
Name: Patrick Pagano
Department: Med-Pharmacology and Chemical Biology
- Country/Region
- USA
For more information, please click Here
